# Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis

> **NCT04205851** · PHASE1 · COMPLETED · sponsor: **Kinevant Sciences GmbH** · enrollment: 36 (actual)

## Conditions studied

- Inflammation
- Rheumatic Diseases

## Interventions

- **DRUG:** KIN-1901
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04205851
- **Lead sponsor:** Kinevant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-12
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-04-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205851, "Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04205851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*